Hemolytic Reaction Therapy application to Cancerous Tumors

The premise presently applies to tumors where the entry and exit of blood to the tumors can be accessed.  It is presently only theoretical.  Yet, with further development, as it proposes to use the propensity of a cancer tumor to fuel itself from the blood of it's host, against it in a way that does not fight it, but makes it either go into Hemolytic Shock and die or causes it to become a source of Hemolytic Shock to the surrounding tissue whereupon the body's own defenses will kill it, either way the process intends to make the diseased tissue of a Cancer Tumor no longer able to hide behind it's biological similarity to the Patient's healthy tissue, in order to ward off the body's own defense systems and survive while it propagates.  The result: either self-destruction or tissue rejection induced death of the tumor, is the intended result of a very unusual procedure involving isolation of the blood flow to the tumor, introduction of uniquely modified blood components (recycled at the outflow part of the patient's vascular system back into the intake by the tumor, with additive components) leading to the induction of a hemolytic response of one kind or the other.  Here is a summary of the Stages of the proposed therapy.

Stage 1.  Cultures of the Blood and Tumor are taken to ascertain which base cell structures the tumor came from, and which incompatible blood type can be used (RH or Type) to carry the piggyback hemolytic inductor or accelerant.  The Blood type chosen must be one which, while incompatible with the donor, is not sufficiently so as to induce hemolytic anaphylactic shock or death.  A proper mix ratio will insure that the tumor ingests sufficient incompatible blood to induce the desired Type A or Type B HRT response from the tumor.  The mix ratio is called "the Hemolytic Reaction Catalyst" Body.

Stage 2. Upon typing the properly incompatible blood type or RH or both, blood harvested from incompatible donors is partly RH inhibited by a buffered inhibition agent, bilorubin, and then the hemolytic inductors (usually an  antibiotic such as may be ordinarily used in treatment of Hepatitis C may be used, but it must be rendered 98% inert either by radiation or exposure to heat or cold).

Stage 3.  It is important that extra-venous infusers be attached using specially designed inlet catheters to more than 90% of all blood supply veins to the tumorous tissues.  This process involved fan-shaped infusers with expansion caps that are expanded to cut off ordinary blood flow by 95% to the tissue in question to allow selective blood replacement by the infusion supply.

Stage 4.  Localizing the outflow of blood from the return veins from the areas of the tumorous growth is vital, through injection of the return ejection tubing, which removes the tainted blood from the area of the tumor tissue.  The near complete microsurgical isolation of the tumor so that the  Hemolytic Reaction Catalyst body can flood the Tumor long enough to cause a change in the Tumor's nature.  It is vital that the blood flow of either HRC or host blood not be removed from the surrounding tissues to insure the survival of the patient.

Stage 5.  The expansion collars on the infusers are gradually expanded and the patient's blood supply to the tumorous tissue is gradually supplanted by the HRC body fluid.  At this stage, it is possible that allergic response might occur from the healthy tissue in the surrounding area.  Introduction of an anti-histamine compound is suggested if signs show of same.

Stage 6.  For an ongoing period of time, the HRC body is pumped through the diseased tissue zone, at blood pressure regulated by the patient wearing a continuous electronic BP monitor, allowing regulatory control for the sake of tissue fluid balance and to protect the patient against stroke.  The electrolytic balance and content of the HRC body fluid is supplemented progressively as the diseased tissue consumes it, using the artificial micro-heart and micro-lungs provided with the infusor system.

Stage 7.  As the flow continues, the HRC body is constantly monitored and it's content, oxygenation, water content, plasma content, and toxicity managed by the support computer built into the infusor system.

Stage 8.  After each four hour period of treatment, tissue is biopsied from the tumor to ascertain whether a Type A or Type B reaction is present.  The infusion is continued for a period of as long as four days. 

Stage 9.  Reaction. In the case of a Type A reaction, the tumor tissue will begin to swell and/or rupture, cell walls will begin to collapse, without evidence of similar behavior from the surrounding tissues.  Eventually, the tissue will turn from white/brown/black to reddish with yellow and then to red/brown as death of the tumor is onset.  Infusion can stop when the tumor dies or at the end of four days, and repeated as frequently as two days after each complete round. In the case of a Type B reaction, the tumor tissue will enlarge very slightly, but the surrounding tissue will begin to spongify as if reacting to the presence of foreign body presence.  This reaction occurs when the blood body cells begin to ingest with the tumor and cause cellular conversion in the tumor to the selected incompatibility of the infusion.  When  Type B reaction is present, it is crucial to allow the cultural dominance of the incompatibility to take root in the tumor.  Cells of the tumor afflicted, will no longer be able to communicate their degenerative code to ordinary tissue of the body, halting the Tumor.  However, density studies of the percentage of the tumor which has converted to the RH or Blood Typing factor in their mimetic structure, it must reach 98% by discontinuation of the procedure, or the infusion must continue until it does. 

Stage 10. Within 72 hours of terminating the infusion, tissue rejection or tissue exhumation will commence on a grand scale, and toxic side effects will have commenced.  Oxygen and Anti-biotic therapy must start to protect the healthy tissue from infection or toxification by biological byproducts of either the tumor death or immune response rejection, whichever be the case.

It is not recommended that the patient be subjected to surgical removal of tissue during the procedure. The induction of a hemolytic response in Cancer Tumors creates a very grave risk of spreading the cancer, if it is not removed from the body by ordinary auto-immune or rejection responses of the body's endocrinal/cardiac systems.  Antibiotics and Oxygen run the greatest likelihood of insuring the patient is not infected metasticly by the fragments of the Tumors as they die or are dissolved by rejection response.  Either way, repeated therapy should demonstrate the complete reversal of cancer infiltration within 90 days of commencement of the procedure, without likelihood of re-infiltration.  Microcellular structure left behind after the procedure tend to permanently inhibit the growth of new tumors on the old growth site, preventing a very common origin of original cancer tumor development.

BEFOREHAND.  It is crucial that a high organic content diet, vitamin supplement, rest, mild exercise, clean water and elimination of toxins be undertaken under supervision by the patient.  No coffee, alcohol, narcotics, tobacco, excessive fats, carcinogens, raw or cooked red meat, raw or cooked pork, or large volumes of sugar or salt should be consumed by the patient for at least six months prior to the procedure, to eliminate enzymes and biological weaknesses that could otherwise encourage the tumors to thrive while under therapy by the Hemolytic Reaction Treatment Process, as a protective matter.  Individuals should be given a balanced diet, ample sleep, substantial quantities of Vitamin C, B, E, and minerals such as Calcium, Zinc, Boron, Strontium, and other nutrient supplements on a daily basis to insure that a surplus of raw materials exists in the blood so as to insure that the patient's system responds well in either the Type A or Type B scenario.  RBC, Immunoglobulin, iGA and HGH levels can be enhanced in the patient but must not be applied to the Cancer tumor directly so as not to trigger spontaneous tumor metasticization during the HRT Process.


Proposal conceived and written by "Scientist 237"
  of the ACSA Study Group on Cancer.

2004 ACSA Inc.  All rights reserved.